

CERTIFICATE OF MAILING UNDER 1.8

I hereby certify that this paper or fee is being deposited with the United States Postal Service with sufficient postage with service under 37 C.F.R. 1.8 on the date indicated below and is addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Signature

Date

8/8/2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

The application of:

Mark Leslie Smythe, et al.

Serial No. 09/806,036

Filed: July 5, 2001

For: SYNTHESIS OF CYCLIC PEPTIDES

§
§
§
§
§
§
§
§

Confirmation No.: 3406

Group Art Unit: 1653

Examiner: Kam, Chih Min

Docket No.: 36677.29

INFORMATION DISCLOSURE STATEMENT

Mail Stop AMENDMENT
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 CFR §1.56, and in accordance with the practice under 37 CFR §1.97 and §1.98, the Examiner's attention is directed to the documents listed on the enclosed modified Form PTO-1449. No inference should be made that the cited references are in fact material, are in fact prior art, or that no better art exists.

This Information Disclosure Statement is being filed more than three months after the United States filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Action under §1.113 or Notice of Allowance under §1.311 (37 CFR §1.97(c)).

In compliance with the duty of disclosure under 37 CFR §1.56, and in accordance with the practice under 37 C.F.R. §1.97 and §1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO-1449. Copies of the listed information are also enclosed. The undersigned first became aware of the cited patents by their inclusion in an International Search Report issued by the European Patent Office on July 16, 2004, the foreign counterpart of the present application. A copy of the search report is enclosed.

Accompanying this transmittal is the \$180.00 fee set forth in 37 CFR §1.17(p) for submission of an Information Disclosure Statement under §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to Deposit Account 08-1394.

08/12/2005 HMARZI1 00000052 081394 09806036

01 FC:1806 180.00 DA


It is respectfully requested that the above information be considered by the Examiner and that a copy of the enclosed Form PTO-1449 be returned indicating that such information has been considered.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Mark D. Moore", written over a horizontal line.

Mark D. Moore, Ph.D.
Registration No. 42,903

Date: 8 AUGUST 2005
HAYNES AND BOONE, LLP
901 Main Street, Suite 3100
Dallas, Texas 75202-3789
Telephone: 713-547-2000
Facsimile: 214-200-0853
File: 36677.29

Place of PTO-1449 Form  U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/806,036
				Filing Date	07/05/2001
				Applicant(s)	Mark Leslie Smythe, et al.
				Art Unit	1653
				Examiner Name	Kam, Chih Min
				Attorney Docket Number	36677.29 (4050.001200)
SHEET	1	OF	1		

U. S. PATENT DOCUMENTS				
Examiner's Initials	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document

FOREIGN PATENT DOCUMENTS					
Examiner's Initials	Cite No.	Foreign Patent Document (Country Code - Number - Kind)	Publication Date MM-DD-YYYY	Patentee or Applicant of Cited Document	Translation Y/N

NON-PATENT LITERATURE DOCUMENTS		
Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item, date, page(s), volume-issue number(s), publisher, city/country where published
		European Search Report for Application No. EP 99948610.3
		Examination Report for Application No. EP 99948610.3
		SHINOBO SAKURADA , et al., <i>Antinociceptive Mechanism of [D-Arg-2]-Dermorphin Tripeptide Analogs</i> , The Journal of Pharmacology and Experimental Therapeutics, 1992, pages 793-799, Vol. 263, No. 2
		SEVERO SALVADORI , et al., <i>Synthesis and Pharmacological Activity of Dermorphin and its N-terminal Sequences</i> , International Journal of Peptide Protein Research, 1982, pages 536-542, Vol. 19
		FLORINE CAVELIER-FRONTIN , et al., <i>How to Perform Small Peptide Cyclizations</i> , Journal of Molecular Structure, 1993, pages 125-130, Vol. 286
		ANGELIKA EHRLICH , et al., <i>Cyclization of all-L-Pentapeptides by Means of 1-Hydroxy-7-azabenzotriazole-Derived Uronium and Phosphonium Reagents</i> , Journal of Organic Chemistry, 1996, pages 8831-8838, Vol. 61, No. 25
		DENISE D. BEUSEN , et al., <i>Conformational Mimicry: Synthesis and Solution Conformation of a Cyclic Somatostatin Hexapeptide Containing a Tetrazole cis Amide Bond Surrogate</i> , Biopolymers, 1995, pages 181-200, Vol. 36, No. 2
		M. ELSEVIERS , et al., <i>Evidence for the Bioactive Conformation in a Cyclic Hexapeptide Analogue of Somatostatin Containing a cis-peptide Bond Mimic</i> , Biochemical and Biophysical Research Communications, July 29, 1988, pages 515-521, Vol. 154, No. 2
		THOMAS RÜCKLE , et al., <i>Pseudo-Prolines in Cyclic Peptides: Conformational Stabilisation of cyclo[Pro-Thr(PSI<Me, Me>pro)-Pro]</i> , Tetrahedron, 1999, pages 11281-11288, Vol. 55, No. 37.
		PAOLO BOTTI , et al., <i>Cyclic Peptides from Linear Unprotected Peptide Precursors through Thiazolidine Formation</i> , Journal of American Chemical Society, 1996, pages 10018-10024, Vol. 118, No. 42
		LIANSHAN ZHANG , et al., <i>Synthesis and Application of Unprotected Cyclic Peptides as Building Blocks for Peptide Dendrimers</i> , Journal of American Chemical Society, 1997, pages 2363-2370, Vol. 119, No. 10
		LIANSHAN ZHANG , et al., <i>Lactone and Lactam Library Synthesis by Silver Ion-Assisted Orthogonal Cyclization of Unprotected Peptides</i> , Journal of American Chemical Society, 1999, pages 3311-3320, Vol. 121, No. 14
		YANG SHAO , et al., <i>A Novel Method to Synthesize Cyclic Peptides</i> , Tetrahedron Letters, 1998, pages 3911-3914, Vol. 39, No. 23

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.